2-benzamido-3-methoxybenzamide | 172462-99-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-benzamido-3-methoxybenzamide
• 英文别名: 2-N-Benzoylamino-3-methoxybenzamide
• CAS: 172462-99-6
• 化学式: C₁₅H₁₄N₂O₃
• 分子量: 270.288
• InChiKey: WQEYFZHCTURDIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-benzamido-3-methoxybenzamide 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 6.0h， 以84%的产率得到8-methoxy-2-phenylquinazolin-4-one
  参考文献：
  名称：

  2-芳基喹唑啉-4-酮作为tankyrases的高选择性和强效抑制剂的构效关系

  摘要：

  Tankyrases (TNKSs) 是 PARP（聚（ADP-核糖）聚合酶）酶超家族的成员，作为治疗药物靶点引起了人们的兴趣，特别是因为它们参与 Wnt 信号传导的调节。合成了一系列在 8 位具有不同取代基的 2-芳基喹唑啉-4-酮。8-甲基（与 8-H、8-OMe、8-OH 相比）与 4'-疏水或吸电子基团一起对 TNKS 提供了最大的效力和选择性。所选化合物与 TNKS-2 的共晶结构表明，与 PARP-1/2 相比，TNKS-2 中 8 位附近的蛋白质更具疏水性，从而使选择性合理化。NAD +-结合位点包含容纳 2-芳基的疏水腔；在 TNKS-2 中，它有一条通往外部的隧道，但在 PARP-1 中空腔是封闭的。8-Methyl-2-(4-trifluoromethylphenyl)quinazolin-4-one 被确定为 TNKSs 和 Wnt 信号传导的有效和选择性抑制剂。这种

  DOI：

  10.1016/j.ejmech.2016.04.041
• 作为产物：
  描述：

  2-氨基-3-甲氧基苯甲酸 在 吡啶 、 ammonium hydroxide 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 2-benzamido-3-methoxybenzamide
  参考文献：
  名称：

  2-芳基喹唑啉-4-酮作为tankyrases的高选择性和强效抑制剂的构效关系

  摘要：

  Tankyrases (TNKSs) 是 PARP（聚（ADP-核糖）聚合酶）酶超家族的成员，作为治疗药物靶点引起了人们的兴趣，特别是因为它们参与 Wnt 信号传导的调节。合成了一系列在 8 位具有不同取代基的 2-芳基喹唑啉-4-酮。8-甲基（与 8-H、8-OMe、8-OH 相比）与 4'-疏水或吸电子基团一起对 TNKS 提供了最大的效力和选择性。所选化合物与 TNKS-2 的共晶结构表明，与 PARP-1/2 相比，TNKS-2 中 8 位附近的蛋白质更具疏水性，从而使选择性合理化。NAD +-结合位点包含容纳 2-芳基的疏水腔；在 TNKS-2 中，它有一条通往外部的隧道，但在 PARP-1 中空腔是封闭的。8-Methyl-2-(4-trifluoromethylphenyl)quinazolin-4-one 被确定为 TNKSs 和 Wnt 信号传导的有效和选择性抑制剂。这种

  DOI：

  10.1016/j.ejmech.2016.04.041

文献信息

• [EN] TANKYRASE INHIBITORS<br/>[FR] INHIBITEURS DE TANKYRASE
  申请人：UNIV BATH

  公开号：WO2014087165A1

  公开（公告）日：2014-06-12

  The present invention relates to a compound of formula I wherein X is C(R6) or N, Y is C or N, and ring A, ring B, R1 and R2 have the meanings defined herein, provided that when ring B is carbocyclic, X is C(R6); or a pharmaceutically acceptable salt or solvate thereof. The compounds are tankyrase-1 and tankyrase-2 inhibitors and are useful in the treatment of a number of conditions, including cancer.

  本发明涉及一种具有式I的化合物，其中X为C(R6)或N，Y为C或N，环A、环B、R1和R2具有本文中定义的含义，前提是当环B为碳环时，X为C(R6)；或其药学上可接受的盐或溶剂。这些化合物是坦克酶-1和坦克酶-2抑制剂，并可用于治疗多种疾病，包括癌症。
• Benzamide analogs useful as PARP (ADP-ribosyltransferase, ADPRT) DNA
  申请人：Newcastle University Ventures Limited

  公开号：US05756510A1

  公开（公告）日：1998-05-26

  A range of 3-oxybenzamide compounds and related quinazolinone compounds are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The compounds disclosed include 3-benzyloxybenzamides, 3-oxybenzamides in which a chain of 5 or more methylene groups terminate in a halogen atom or in a purin-9-yl moiety, certain benzoxazole-4-carboxamide compounds and certain quinazolinone compounds. In formula X and Y together may form a bride --X--Y-- that represents the grouping (a), (b) or (c )wherein R.sup.5 is H, alkyl, aryl or aralkyl.

  揭示了一系列3-氧苯甲酰胺化合物和相关的喹唑啉酮化合物，它们可以作为DNA修复酶聚(ADP-核糖)聚合酶或PARP酶（EC 2.4.2.30）的有效抑制剂，并且因此可以提供用于与损伤DNA的细胞毒性药物或放疗结合使用以增强后者效果的有用治疗化合物。所披露的化合物包括3-苄氧基苯甲酰胺、3-氧基苯甲酰胺，其中5个或更多亚甲基基团的链以卤原子或吡嗪-9-基团结尾，某些苯并噁唑-4-甲酰胺化合物和某些喹唑啉酮化合物。在公式X和Y中，X和Y一起可以形成代表基团(a)、(b)或(c)的桥--X--Y--，其中R.sup.5为H、烷基、芳基或芳基烷基。
• QUINAZOLINONE CONPOUNDS AS CHEMOTHERAPEUTIC AGENTS
  申请人：NEWCASTLE UNIVERSITY VENTURES LIMITED

  公开号：EP0897915A1

  公开（公告）日：1999-02-24

  A range of quinazolinone compounds are disclosed which can act as potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase or PARP enzyme (EC 2.4.2.30), and which thereby can provide useful therapeutic compounds for use in conjunction with DNA-damaging cytotoxic drugs or radiotherapy to potentiate the effects of the latter. The compounds disclosed comprise certain quinazolinone compounds having the general structural formula II or pharmaceutically acceptable salt thereof, characterised in that X' represents hydroxyl, alkyl, alkoxy or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl) group, and Y' represents hydrogen, alkyl or an optionally substituted aryl (e.g. phenyl) or aralkyl (e.g. benzyl) group.

  本发明公开了一系列喹唑啉酮化合物，它们可以作为 DNA 修复酶聚（ADP-核糖）聚合酶或 PARP 酶（EC 2.4.2.30）的强效抑制剂，从而可以提供有用的治疗化合物，与破坏 DNA 的细胞毒性药物或放射治疗一起使用，以增强后者的效果。所公开的化合物包括某些具有通式 II 结构的喹唑啉酮化合物 或其药学上可接受的盐、 其特征在于 X'代表羟基、烷基、烷氧基或任选取代的芳基（如苯基）或芳烷基（如苄基）、 和 Y' 代表氢、烷基或任选取代的芳基（如苯基）或芳烷基（如苄基）。
• Resistance-Modifying Agents. 5. Synthesis and Biological Properties of Quinazolinone Inhibitors of the DNA Repair Enzyme Poly(ADP-ribose) Polymerase (PARP)
  作者：Roger J. Griffin、Sheila Srinivasan、Karen Bowman、A. Hilary Calvert、Nicola J. Curtin、David R. Newell、Louise C. Pemberton、Bernard T. Golding

  DOI：10.1021/jm980273t

  日期：1998.12.1

  Clinical studies concerning the role of poly(ADP-ribose) polymerase (PARP) in the repair of drug- and radiation-induced DNA damage have been impeded by the poor solubility, lack of potency, and limited specificity of currently available inhibitors. A series of 2-alkyl- and 2-aryl-substituted 8-hydroxy-, 8-methoxy-, and 8-methylquinazolin-4(3H)-ones has been synthesized and evaluated for PARP inhibitory activity in permeabilized L1210 murine leukemia cells. 8-Methoxy- and 8-methylquinazolinones (14-34) were readily prepared by acylation of 3-substituted anthranilamides with the appropriate acid chloride, followed by base-catalyzed cyclization. The requisite 8-hydroxyquinazolinones (6, 35-39) were synthesized by demethylation of the corresponding 8-methoxyquinazolinones with BBr3. N-Methylation of 8-methoxy-2-methylquinazolinone (15) with Mel, followed by O-demethylation by BBr3, afforded the control N-3-methylquinazolinones 42 and 43, respectively. In general, an 8-hydroxy or 8-methyl substituent enhanced inhibitory activity in comparison with an 8-methoxy group. 2-Phenylquinazolinones were marginally less potent than the corresponding 2-methylquinazolinones, but the introduction of an electron-withdrawing or electron-donating 4'-substituent on the 2-aryl ring invariably increased potency. This was particularly evident in the 8-methylquinazolinone series (IC50 values 0.13-0.27 mu M), which are among the most potent PARP inhibitors reported to date. N-3-Methylquinazolinones 42 and 43 were essentially devoid of activity (IC50 values > 100 mu M). In studies with L1210 cells in vitro, a concentration of 200 mu M 8-hydroxy-2-methylquinazolinone (6, NU1025) (IC50 value 0.40 mu M) potentiated the cytotoxicity of the monomethylating agent 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide and gamma-radiation 3.5- and 1.4-fold, respectively, at the 10% survival level.
• Griffin; Srinivasan; White, Pharmaceutical Sciences, 1996, vol. 2, # 1, p. 43 - 47
  作者：Griffin、Srinivasan、White、Bowman、Calvert、Curtin、Newell、Golding

  DOI：——

  日期：——